Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 16;9(1):1774314. doi: 10.1080/2162402X.2020.1774314

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Forest plots for (a) overall survival and (b) progression-free survival in studies assessing immune checkpoint inhibitors as first-line therapy.

Hellmann 2019 CheckMate 227, Nivolumab + CHT vs. CHT: We converted 97.72% CI (0.60–1.02) for overall survival and 97.72% CI (0.56–0.95) for progression free survival to 95% CI. Hellmann 2019 CheckMate 227, Nivolumab + Ipilimumab vs. CHT: We converted 97.72% CI (0.65–0.96) for overall survival to 95% CI. Abbreviations: CHT = chemotherapy; CI = confidence interval; ICI = immune checkpoint inhibitor; N = number of patients; PD-L1 = programmed cell death ligand-1.